Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis
EP Europace2013Vol. 15(10), pp. 1412–1420
Citations Over TimeTop 10% of 2013 papers
Aref A. Bin Abdulhak, Abdur Rahman Khan, Imad M. Tleyjeh, John A. Spertus, Susan U. Sanders, Kristy Steigerwalt, Musa A. Garbati, Reem A Bahmaid, Alan P. Wimmer
Abstract
Meta-analysis of currently available studies showed no significant difference in bleeding and thromboembolism between interrupted dabigatran and warfarin therapy in CA of AF. Dabigatran appears to be safe and effective for peri-procedural anticoagulation in CA of AF.
Related Papers
- → Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation(2016)56 cited
- Adherence, persistence, and switching patterns of dabigatran etexilate.(2013)
- → Dabigatran Versus Warfarin in Atrial Fibrillation(2014)12 cited
- → Drug Interactions and Risk of Bleeding among Patients with Atrial Fibrillation (AF) Discharged with Warfarin(2006)1 cited
- → Letter to the Editor(2015)